Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
BridgeBio Pharma, Inc.
BBIO
NASDAQ·Healthcare·Biotechnology·Mkt cap $14.6B
$76.26
▲ +2.33%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$42.09 - $84.94
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 74.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diversified pipeline of 30 programs reduces development risk and provides multiple revenue opportunities
- Strategic academic partnerships with Stanford and UC Berkeley provide access to cutting-edge research and early-stage assets
- Focus on genetically-defined rare diseases with high unmet medical needs and potential for premium pricing
- Experienced management team with deep expertise in genetic disease biology and drug development
Bear Case
2 risks
- Average volatility.
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Strong growth ahead
Strong revenue growth (126% YoY)
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Stable
+1.9% over 3m
Quality
Excellent
High-growth business (355% revenue growth, 94% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying BBIO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 27, 2026
MAY 7, 2026
Reported EPS of -$0.84 vs -$0.70 consensus (-20.0% surprise). Revenue of $194.5M vs $178.1M expected (+9.2%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-20.0%
Next: Apr 27, 2026
Revenue trend · last 8Q
—
—
+237%
-45%
+5000%
+4318%
+2521%
+67%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$2.2M
$2.7M
$5.9M
$116.6M
$110.6M
$120.7M
$154.2M
$194.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
-84.3%
Wall Street consensus
9 analysts · 89% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
89%
Hold
11%
Sell
0%
Median Price Target
$104.00
▲ +36.4% vs $76.26
Latest: Canaccord · $104.00 · Jun 3, 2026
7 analysts covering